Share
Health Canada has approved the use of the abortion-inducing drug branded as Mifegymiso® in Canada.
Mifegymiso® provides a medical abortion regimen rather than a surgical procedure to induce an abortion. The treatment consists of a combination drug product of mifepristone and misoprostol. It is to be used sequentially for the termination of a developing intra-uterine pregnancy up to a gestational age of 49 days.
Health Canada has been reviewing the Drug Submission for Mifegymiso® since 2012 in an effort to determine the safety, efficacy, and quality of the product. The decision to authorize the drug for the Canadian market was approved July 29, 2015.
Mifegymiso® is approved for physician only dispensing, and will require two visits to a physician. During the first visit, the patient takes one mifepristone-misoprostol combination pill under doctor supervision. At home, they take four more within 12 to 24 hours. The patient then returns to their doctor for a post-treatment examination within one to two weeks.
The College will be monitoring any updates to the conditions set out by Health Canada, particularly if the restrictions on physician only dispensing expands to include other regulated health professionals.
Share
